A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement

BackgroundAlectinib has demonstrated promising disease-free survival (DFS) benefit for early-stage non-small cell lung cancer (NSCLC) patients with ALK rearrangement positive in phase 3 ALINA trial. However, real-world evidence for the efficacy and safety of alectinib in early-stage ALK-positive NSC...

Full description

Bibliographic Details
Main Authors: Zeng-Hao Chang, Teng-Fei Zhu, Wei Ou, Hao Jiang, Si-Yu Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Oncology
Subjects:
adjuvant therapy
anaplastic lymphoma kinase-tyrosine kinase inhibitor
alectinib
NSCLC
dfs
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1422035/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1422035/full

Similar Items